CONCORDBIO
Concord Biotech
Each stock's 10,000-path forecast, rendered as light.
Concord Biotech (CONCORDBIO) Stock Analysis & Case Study
Is CONCORDBIO a good buy? The data-driven verdict.
Concord Biotech (CONCORDBIO) trades at ₹1,338,on the numbers it tread carefully, a Downstox Snapshot Score of 34/100.
On the numbers, Concord Biotech (CONCORDBIO) tread carefully, a Downstox Snapshot Score of 34/100, weighing expensive at 53.1× earnings, ROE of 13.8%, a 35% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
CONCORDBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is CONCORDBIO overvalued? CONCORDBIO P/E vs its sector
CONCORDBIO's P/E of 53.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.80% dividend yield is below the peer median of 1.65%.
CONCORDBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of CONCORDBIO history (-7%/yr drift, 45%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| CONCORDBIO 2027 | ₹615 | ₹1,104 | ₹1,980 | -16% |
| CONCORDBIO 2028 | ₹405 | ₹916 | ₹2,059 | -30% |
| CONCORDBIO 2029 | ₹281 | ₹768 | ₹2,120 | -42% |
| CONCORDBIO 2030 | ₹197 | ₹639 | ₹2,092 | -51% |
| CONCORDBIO 2031 | ₹144 | ₹538 | ₹1,961 | -59% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability CONCORDBIO goes up, or doubles?
The bull case for CONCORDBIO
- A healthy 13.8% return on equity.
- Strong ROCE (18.2%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,120.
The bear case & risks
- A rich 53.1× P/E leaves a thin margin of safety if growth slows.
- The probability model is cautious 12 months out, only a 35% chance of finishing above today's price.
- High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹281.
CONCORDBIO volatility & expected range, how bumpy is the ride?
Over the last 2.0 years CONCORDBIO compounded at -7%/year with annualized volatility of 45%. That volatility implies a 1-year 80% range of ₹615–₹1,980, the honest backbone behind any single price target.
CONCORDBIO price forecast, the full 60-month probability fan
CONCORDBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds CONCORDBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the CONCORDBIO price target & forecast page.
CONCORDBIO Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. CONCORDBIO scores 4/9,mixed financial health.
CONCORDBIO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy CONCORDBIO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 35.1% | 2.8× |
| ZerodhaCHEAPEST | 35.1% | 2.8× |
| DhanCHEAPEST | 35.1% | 2.8× |
Compare every broker on the CONCORDBIO MTF page.
CONCORDBIO vs peers,sector comparison
About Concord Biotech: sector, index & market-cap context
Concord Biotech (CONCORDBIO) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹13,978 Cr. See more Nifty 200 stocks.
How the CONCORDBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Concord Biotech's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CONCORDBIO analysis, FAQs
Is Concord Biotech (CONCORDBIO) a good buy?
On the numbers, Concord Biotech (CONCORDBIO) tread carefully, a Downstox Snapshot Score of 34/100, weighing expensive at 53.1× earnings, ROE of 13.8%, a 35% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is CONCORDBIO overvalued or undervalued?
CONCORDBIO trades at 53.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the CONCORDBIO share price target for 2031?
CONCORDBIO's probability-weighted 2031 median target is ₹538, with an 80% range of ₹144–₹1,961 (10,000-path Monte-Carlo).
What is the probability CONCORDBIO doubles in 5 years?
The modelled probability of CONCORDBIO reaching ₹2,630 (2×) within 5 years is 6%.
What is the bull case for CONCORDBIO?
A healthy 13.8% return on equity. Strong ROCE (18.2%) shows the core business earns well above its cost of capital.
What are the risks in CONCORDBIO?
A rich 53.1× P/E leaves a thin margin of safety if growth slows. The probability model is cautious 12 months out, only a 35% chance of finishing above today's price. High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.